Presentation at Big Data Belfast

RNS Number : 9199Q

Diaceutics PLC

24 October 2019

 

Diaceutics PLC

("Diaceutics" or the "Company")

Presentation at Big Data Belfast

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces that it will attend the Big Data Belfast conference as an invited speaker at the ICC Waterfront in Belfast on 24 October. Big Data Belfast is one of the leading data and technology events on the island of Ireland, driving thought leadership in one of the most exciting and expansive business clusters. This established conference has been running for seven years, featuring global data and analytics experts and best in class data driven organisations.

Derek Hosty, Head of Global Data at Diaceutics will deliver a presentation during the Artificial Intelligence and Machine Learning section of the conference entitled 'Using Big Data to make Better Decisions in Healthcare.' The presentation will be available on the Company's website from the end of the day and can be accessed via this link:

https://www.diaceutics.com/using-big-data-to-make-better-decisions-in-healthcare/

The Company's proprietary data offering combines diagnostic testing, claims and prescription data providing actionable insights for 115m+ patient records covering 47 deductive pathways in 35 global markets. Diaceutics' presentation will demonstrate how smart application of the Company's data analytics can significantly impact outcomes for patients in need of precision medicine therapies using a case study of metastatic lung cancer.

Enquiries:

Diaceutics PLC		www.diaceutics.com
Peter Keeling, Chief Executive Officer			via Walbrook PR
Philip White, Chief Financial Officer
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy				Mob: [phone]
Paul McManus				Mob: [phone]

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

 

END

 

 

NRABUBDGRBDBGCX